Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ferriprox | Deferiprone | Transfusional iron overload | List with clinical criteria and/or conditions | Complete | ||
Ferriprox | deferiprone | Transfusional iron overload | Reimburse with clinical criteria and/or conditions | Complete | ||
Ferinject | ferric carboxymaltose | Iron deficiency anemia | Received | |||
Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Received | |||
Fentora | Fentanyl buccal | Pain (breakthrough), cancer (adults) | Do not reimburse | Complete | ||
Faslodex | Fulvestrant | Locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Withdrawn | |||
Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Do not list | Complete |